Previous data in rat conductance vessels indicated that cellular mevalonate contributes to vascular tone (7, 8) . In a recent publication (9), we provided evidence that mevalonate availability was a novel regulatory mechanism contributing to the control of vascular tone and systemic blood pressure. In that study, in vitro exposure of rat conductance vessels (aorta) to lovastatin increased the response to vasoconstrictors and decreased endothelium-dependent and independent relaxations. These effects were independent of tissue changes in cholesterol content and reversed by co-incubation with mevalonate, suggesting that mevalonate derivatives other than cholesterol itself were vasoactive. Experiments conducted in vivo further supported this hypothesis, with lovastatin and mevalonate respectively increasing and decreasing systolic blood pressure in normotensive as well as hypertensive rats. Those observations were recently confirmed by Yamori et al. in a preliminary communication (10), using pravastatin, another HMG-CoA reductase inhibitor.
Introduction
Previous data in rat conductance vessels indicated that cellular mevalonate contributes to vascular tone and systemic blood pressure control. Using exogenous mevalonate (M) or lovastatin, a 3-hydroxy-3-methyl-glutaryl. CoA (HMGCoA) reductase inhibitor (L), we characterized the role of mevalonate availability in resistance artery function, both in experimental animals and humans. Rat mesenteric artery resistance vessels (MARV, n = 9) were incubated for 48 h with either L, M, L + M, or vehicle (V) and tested for reactivity to NE, serotonin, acetylcholine, atrial natriuretic peptide, and sodium nitroprusside (SNP). Lovastatin increased sensitivity to NE (P < 0.03) and serotonin (P < 0.003), and significantly impaired the response to all three vasodilators. These effects were reversed by co-incubation with mevalonate. Mevalonate alone had no effect. In separate experiments, intravascular free Ca2`concentration (ivfCa2") was determined in fura-2AM loaded MARV. Basal rCa2+ was increased after a 48-h exposure to L (52.7±4.6 nM, L, vs. 29.7±2.4 nM, V, n = 12, P < 0.003), as were IvfCa+ levels following stimulation with low (100 nM) NE concentrations. Similar 1vfCa2`c oncentrations were achieved during maximum contraction with NE (10 mM) in both groups. Human resistance arteries of human adipose tissue were also studied. Lovastatin increased the sensitivity to NE (ED50 = 372±56 nM, V, and 99±33 nM, L,P < 0.001) and significantly decreased the relaxation to acetylcholine and SNP of human vessels. We conclude that mevalonate availability directly contribute to resistance vessel function and vascular signal transduction systems in both experimental animals and humans. The study calls for the identification of non-sterol, mevalonate-derived vasoactive metabolites, and suggests that disorders of the mevalonate pathway can (7, 8) . In a recent publication (9), we provided evidence that mevalonate availability was a novel regulatory mechanism contributing to the control of vascular tone and systemic blood pressure. In that study, in vitro exposure of rat conductance vessels (aorta) to lovastatin increased the response to vasoconstrictors and decreased endothelium-dependent and independent relaxations. These effects were independent of tissue changes in cholesterol content and reversed by co-incubation with mevalonate, suggesting that mevalonate derivatives other than cholesterol itself were vasoactive. Experiments conducted in vivo further supported this hypothesis, with lovastatin and mevalonate respectively increasing and decreasing systolic blood pressure in normotensive as well as hypertensive rats. Those observations were recently confirmed by Yamori et al. in a preliminary communication (10), using pravastatin, another HMG-CoA reductase inhibitor.
Resistance arteries, including mesenteric artery resistance vessel (MARV), are critical determinants of systemic blood pressure (11, 12) . Therefore, the combined observation of impaired MARV reactivity and increased BP in animals receiving lovastatin (9) led us to postulate that lovastatin inhibition of the mevalonate pathway of resistance vessels increased vascular resistance and elevated systemic blood pressure. That hypothesis required experimental evidence of a direct effect of the drug on resistance vessels. Therefore, our first objectives in the present study was to describe the direct, in vitro effect of lovastatin and mevalonate on rat resistance vessels.
In our earlier study (9) , lovastatin appeared to act on several pathways including NE-induced contraction and acetylcholine and sodium nitroprusside (SNP)-induced relaxation. It is known that stimulation of membrane receptors, such as the adrenergic and muscarinic receptors, triggers the elevation of 1 . Abbreviations used in this paper: HMG-CoA, 3-hydroxy-3-methylglutaryl CoA; ivfCa2", intravascular free calcium; L, lovastatin; LM, lovastatin+mevalonate; M, mevalonate; MARV, mesenteric artery resistance vessels; SNP, sodium nitroprusside. smooth muscle intracellular Ca2". This, in turn, promotes contraction by catalyzing actin-myosin polymerization. Thus, we speculated that lovastatin modulates vascular reactivity by modifying intravascular levels of Ca2". The experimental demonstration of this point was our second objective.
Since our earlier experiments (9) were conducted with rat vessels, the relevance of the concept of mevalonate availability to other species including humans was questionable. This issue is of importance not only because the ultimate goal of applied medical research is the extension of the findings to humans, but also because lovastatin and other HMG-CoA reductase inhibitors are currently prescribed to millions of individuals to lower plasma cholesterol. Therefore, our last objective was to characterize the effect of lovastatin on human resistance vessels.
Methods
Reagents. NE, acetylcholine, SNP, serotonin, rat synthetic atrial natriuretic peptide (ANP), DL-mevalonic acid lactone (mevalonolactone), transferrin and insulin were obtained from Sigma (St. Louis, MO). Fura-2AM was purchased from Molecular Probes (Eugene, OR). Lovastatin was a gift from Merck Sharp Dohme (Rahway, NJ).
Animal vessels. 12-14-wk-old male Wistar rats (Charles River Breeding Laboratories, Inc., Boston, MA) were used for all experiments. MARV (200-300 mm diameter) were isolated as previously described (13) . Four vascular segments (1.5-2 mm length) from the second branch of the mesenteric artery were prepared from each animal (n = 9) and studied after a 48-h incubation with either lovastatin (L, 5 Ag/ml), mevalonolactone (M, 10 mM), lovastatin + mevalonolactone (LM, 5 jg/ml and 10 mM, respectively), or DMSO as vehicle (V, 0.1% vol/ vol). Preliminary experiments with shorter incubation time (24 h) were also conducted (three arterial segments per animal incubated with either lovastatin, mevalonate or DMSO, n = 9 animals). All incubations were performed in DME/F-12 supplemented with antibiotics (penicillin and streptomycin), transferrin (5 mg/liter) and insulin (5 mg/liter) at 37°C under a 5%-CO2 atmosphere.
Human vessels. Four females and four males whose ages ranged from 44 to 74 and averaged 60.5 yr were recruited in the Surgery department of our institution. They were admitted for lung cancer (one subject) or for peripheral vascular diseases with or without coronary artery disease (2 and 5 subjects, respectively). Four patients were hypertensive and three were diabetic. Plasma cholesterol levels ranged from 160 to 240 mg/dl. None of them was receiving HMG-CoA reductase inhibitors at the time of the study. Small arteries were isolated from biopsies of subcutaneous fat after informed consent from the patients. The protocol was approved by the O.H.S.U. Institution Review Board. After careful dissection, two arterial segments per biopsy were incubated for 48 h in DME supplemented with antibiotics (37°C, 5%-CO2 atmosphere), one with lovastatin (5 mg/ml), the other with DMSO.
Measurement of vascular reactivity. Rat or human arteries were mounted on a wire myograph capable of measuring isometric tension and tested for reactivity to vasoconstrictors and vasodilators in the absence of extracellular drug (14) (15) (16) . The reactivity to NE and serotonin was first determined. Then, relaxation was examined after precontraction with NE. Endothelium-dependent relaxation was tested with acetylcholine; endothelium-independent relaxation with SNP, a direct activator of smooth muscle soluble guanylate cyclase, and with ANP (0.1 jIg/ ml), an activator of the particulate guanylate cyclase. Responses are reported as absolute force normalized to axial length of the vessel (active tension in mN/mm) for contractions or as percent (%) of pre-contraction with NE for relaxations (100% equals no relaxation). When appropriate, ED50 was calculated.
Determination of intravascular free calcium (if Ca2") concentration. These experiments (n = 8-13) were conducted in MARV exposed to lovastatin (5 jg/ml) or vehicle for 48 h. Before being mounted in the myograph, MARV were loaded with 50 AM fura-2AM, a fluorescent Ca2+ indicator (17) , in Hepes (10 mM)-buffered physiological saline, Results 24-h incubation of rat MARV with lovastatin had little effect on vessel reactivity. There was an increased maximum response to NE (5.27±0.19 mN/mm and 4.41±0.34 mN/mm, P < 0.04 for L and V, respectively), and a left-shift of the dose-response curve (Fig. 1) . However, the decrease of NE-ED50 did not reach statistical significance: 116.3±19.2 nM (L) vs. 245.6±63.0 nM (V), P = 0.09. Mevalonate had no effect on the response of the vessels to NE (Fig. 1) . The responses to serotonin, acetylcholine, SNP and ANP were identical in control, lovastatin and mevalonate-treated arteries (data not shown).
48-h incubation with lovastatin significantly increased the sensitivity of MARV to NE. ED50 (nM) were 182±60 and 33±8 for V and L, respectively (P < 0.03). No change in the maximum response to the hormone was observed (Fig. 2) . As shown on the same figure, addition of mevalonate to the medium, together with lovastatin, normalized the response to NE (ED50 = 232+47 nM, P < 0.004 vs. L, P = NS vs. V), while mevalonate alone decreased the sensitivity to NE (ED50 = 232±47 nM, P = 0.06 vs. V). Similarly, the sensitivity to serotonin was increased by lovastatin and normalized by mevalonate addition (Fig. 3) . ED50 (nM) were 138±21 (V), 61±7 (L, P < 0.003) and 184±34 (LM, P < 0.005 vs. L, P = NS vs. V). Mevalonate alone had no effect on the response to serotonin (ED50 = 186±25 nM, P = NS vs. V). A significant impairment of the acetylcholine-induced relaxation was observed in vessels incubated ( maximum response (Fig. 4) . Addition of mevalonate significantly reversed the effect of lovastatin (same figure). Mevalonate alone had no effect. Because the ANP-dependent relaxation of the resistance vessels is slow to develop, the rate of relaxation rather than the dose-response to ANP was determined for each preparation (Fig. 5) 7) . ivfCa2+ levels following stimulation with low NE concentrations (100 nM) were significantly higher in lovastatin-treated arteries than in control vessels. In contrast, similar ivfCa2+ concentrations were achieved during maximum contraction (10 ,uM NE).
Exposure of human resistance arteries (270±19 mm diameter) to lovastatin induced vascular reactivity changes similar to those observed in the rat vessels. The sensitivity but not the maximum response to NE was increased (Fig. 8) . ED50 (nM) were 372±56 and 99 ±33 for V and L, respectively, P < 0.001). Both duced as compared to controls ( Fig. 9 and 10 ). There was no relationship between the effects of lovastatin and patient characteristics (data not shown).
Discussion
The study demonstrates that mevalonate availability has a direct impact on the functional properties of resistance arteries: mevalonate deficiency increases intracellular Ca2", enhances the response to vasoconstrictors and impairs the response to vasodilators, whereas addition of mevalonate to the vessels restores pressor and depressor responsiveness. The study confirms in resistance vessels our previous findings in conductance vessels and provides evidence that mevalonate availability also regulates the contractility of resistance arteries in humans.
Lovastatin was used as a means to limit mevalonate production and cellular availability. The specificity of action of the drug was established by the ability of exogenous mevalonate At these concentrations, lovastatin certainly reduces cellular mevalonate availability, but does not likely affect vascular cholesterol content. Such a situation has been observed in several other reports including ours with rat aortic rings (9, 24, 25). It is not surprising because vascular cholesterol synthesis unlike hepatic or actively replicating cell synthesis is very low (26, 27) . In addition, it is known that excess cholesterol in vascular smooth muscle increases reactivity to vasoconstrictors (28): therefore, if lovastatin had decreased vascular cholesterol concentration in our experiments, one would have expected to observe a decrease in reactivity to NE and not an increase (see Figs. 1, 2, and 8) . Altogether, these observations suggest that lovastatin regulates the metabolic availability of non-sterol product(s) of the mevalonate pathway rather than cholesterol itself. The identity of these metabolites remains to be deter- mined. However, the recently discovered role of mevalonatederived isoprenoids in modulating the activity of GTP-binding proteins (3-6) offers a promising perspective, as vascular reactivity is in large part dependent on GTP-binding protein-mediated signal transduction. Lovastatin increased sensitivity to NE and serotonin. Lovastatin effect on NE is similar to what we observed with aortic rings incubated with the drug and with resistance arteries of animals treated with it (9). The effect on serotonin-induced contraction has not been reported before and suggests that signal transduction steps common to both NE and serotonin are affected. As discussed below, greater availability of ivfCa" should increase sensitivity to NE and serotonin. However, modifications of the affinity of the receptors for their ligands or alteration of signal transduction pathways of the vascular smooth muscle other than intracellular Ca2" could also play a role.
Endothelium-dependent and independent relaxations were reduced by lovastatin in both human and rat resistance arteries. A similar impact of lovastatin was observed previously by us in vivo and in vitro (9) . Our experiments cannot clearly separate the effect of lovastatin on the endothelium from that on the smooth muscle since the response to SNP was also impaired. When considering the relaxation curves of vessels treated with both lovastatin and mevalonate, full relaxation can be achieved with maximum concentrations of SNP (Fig. 5) but not with acetylcholine (Fig. 4) Our study is the first report of an effect of mevalonate availability on human resistance vessels. Together with previous reports, including ours, of impaired mevalonate metabolism in spontaneously hypertensive rats (34-36), our data strongly suggests that genetic or acquired disorders of the mevalonate pathway may cause vascular dysfunction and possibly hypertension in humans. This possibility needs to be explored in future appropriate experiments.
The effect of lovastatin on human arteries also raises the possibility that therapeutic use of HMG-CoA reductase inhibitors has an effect on the vasculature in humans. This possibility has received little attention so far, despite the fact that more than three million patients are currently receiving this therapy in the United States. Investigators have recently provided preliminary evidence of the cardiovascular effects of HMG-CoA reductase inhibitors (37) (38) (39) . However, no study has yet explored the effect of these drugs on resistance arteries ex vivo. Large clinical trials testing the safety of these drugs did not report any adverse impact of HMG-CoA reductase inhibitors on systemic blood pressure (40) (41) . It is essential to note, however, that none of these trials were designed to evaluate properly that outcome: as much as 40% (40) and 55% (41) of the study subjects were hypertensive and/or on antihypertensive medication. Nonetheless, it is possible that the drug levels produced during lovastatin therapy are not high enough to induce a significant change in vascular tone. It is also possible that the reduction in low-density lipoprotein (LDL) and oxidized LDL levels following lovastatin therapy are offsetting the action of the drug on intracellular Ca2+ since LDLs can raise intracellular Ca2+ (42, 43) .
In conclusion, we have demonstrated that mevalonate availability regulates Ca2' homeostasis in small arteries and modulates vascular tone. The existence in the arterial wall of non-sterol mevalonate derivatives with vasoactive properties is postulated as well as the possibility that metabolic disorders of the mevalonate pathway contribute to the pathogenesis of cardiovascular diseases, including essential hypertension. Finally, the study suggests that clinical investigations are necessary in order to fully characterize the vascular consequences of mevalonate deficiency during therapeutic inhibition of HMG-CoA reductase.
